三浦 理
業績等-20241.

Fujimoto D, Hayashi H, Murotani K, Toi Y, Yokoyama T, Kato T, Yamaguchi T, Tanaka K, Miura
S, Tamiya M, Tachihara M, Shukuya T, Tsuchiya-Kawano Y, Sato Y, Ikeda S, Sakata S, Masuda
T, Takemoto S, Otsubo K, Shibaki R, Makino M, Okamoto I, Yamamoto N. Prediction of
prognosis in lung cancer using machine learning with inter-institutional generalizability: A
multicenter cohort study (WJOG15121L: REAL-WIND). Lung Cancer. 2024 Aug;194:107896.
doi: 10.1016/j.lungcan.2024.107896. Epub 2024 Jul 18.PMID: 39043076

2.

Yagishita S, Goto Y, Nishio M, Akamatsu H, Hayashi H, Miura S, Tamada K, Kagamu H,
Hamada A, Ohuchi M, Gemma A, Yoshino I, Misumi T, Hata A, Hara S, Kijima T, Masaki F,
Iwasawa S, Nakagawa S, Tatsuno M, Mitsudomi T. Real-World Pharmacokinetics, Effectiveness,and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An
Exploratory Study of J-TAIL. JTO Clin Res Rep. 2024 May 16;5(7):100683. doi:
10.1016/j.jtocrr.2024.100683. eCollection 2024 Jul.PMID: 39091595

3.

Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T,
Soda S, Fujiwara T, Asao T, Nakamichi S, Kawamura T, Inomata M, Nakashima K, Ito K, Goto
Y, Umeda Y, Hirai S, Ushio R, Yokoo K, Takeda T, Fukui T, Ishihara M, Osaki T, Kubo S,
Fujiwara T, Yamamoto C, Tsuda T, Tamura N, Hosokawa S, Chihara Y, Ikeda S, Furuya N,
Nakahara Y, Miura S, Okamoto H. Real-World Data on Subsequent Therapy for First-Line
Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk
Study TORG-TG2101). Target Oncol. 2024 Apr 13. doi: 10.1007/s11523-024-01048-x. Online
ahead of print.PMID: 38613731

4.

Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O,
Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K,
Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama
K, Yamamoto N, Nakagawa K, Okamoto I. Atezolizumab and Platinum Plus Pemetrexed With or
Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3
Randomized Clinical Trial. JAMA Oncol. 2024 Mar 1;10(3):315-324. doi:
10.1001/jamaoncol.2023.5258.PMID: 38127362

5.

Shibaki R, Fujimoto D, Nozawa T, Sano A, Kitamura Y, Fukuoka J, Sato Y, Kijima T, Matsumoto
H, Yokoyama T, Miura S, Hata A, Tamiya M, Taniguchi Y, Sugisaka J, Furuya N, Tanaka H,
Yamamoto N, Koh Y, Akamatsu H. Machine learning analysis of pathological images to predict
1-year progression-free survival of immunotherapy in patients with small-cell lung cancer. J
Immunother Cancer. 2024 Feb 15;12(2):e007987. doi:
10.1136/jitc-2023-007987.PMID: 38360040-20231.

Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T,
Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada
T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa
K. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell

Lung Cancer. JAMA Netw Open. 2023 Dec 1;6(12):e2347700. doi:
10.1001/jamanetworkopen.2023.47700.PMID: 38100106
2.

Masuda T, Miura S, Sato Y, Tachihara M, Bessho A, Nakamura A, Miyawaki T, Yoshimine K,
Mori M, Shiraishi H, Hamai K, Haratani K, Maeda S, Tabata E, Kitagawa C, Tanizaki J, Imai T,
Nogami S, Yamamoto N, Nakagawa K, Hattori N. Significance of micro-EGFR T790M
mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer. Sci Rep.
2023 Nov 13;13(1):19729. doi: 10.1038/s41598-023-45337-3.PMID: 37957228

3.

Wakuda K, Yamaguchi H, Kenmotsu H, Fukuda M, Ito K, Tsuchiya-Kawano Y, Tanaka K, Harada
T, Nakatani Y, Miura S, Yokoyama T, Nakamura T, Izumi M, Nakamura A, Ikeda S, Takayama
K, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K. A Phase 2 Single-Arm Study ofOsimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for theFirst-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L). JTO Clin Res Rep. 2023
Oct 12;4(12):100587. doi: 10.1016/j.jtocrr.2023.100587. eCollection 2023 Dec.PMID: 38046380

4.

Wakuda K, Kenmotsu H, Sato Y, Nakamura A, Akamatsu H, Tachihara M, Miura S, Yokoyama
T, Mori K, Nakagawa K, Yamamoto N. Randomized, open-label phase II study of brigatinib andcarboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with
ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol
design of the B-DASH study (WJOG 14720 L). BMC Cancer. 2023 Sep 25;23(1):902. doi:
10.1186/s12885-023-11417-w.PMID: 37749521

5.

Tachihara M, Hata A, Tokito T, Hara S, Okada H, Miura S, Sato Y, Tabata E, Watanabe H,
Takayama Y, Toyozawa R, Ota K, Wakuda K, Nakamura A, Shimokawa M, Yamamoto N,
Nakagawa K. Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated
Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A
Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).

JTO Clin

Res Rep. 2023 Aug 23;4(10):100569. doi: 10.1016/j.jtocrr.2023.100569. eCollection 2023
Oct.PMID: 37822699
6.

Fujimoto D, Miura S, Tomii K, Sumikawa H, Yoshimura K, Wakuda K, Oya Y, Yokoyama T,
Kijima T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Tokito T, Murakami S, Tamiya A,
Yokouchi H, Watanabe S, Yamaguchi O, Morinaga R, Jodai T, Ito K, Shiraishi Y, Kogure Y,
Shibaki R, Yamamoto N. Pneumonitis associated with pembrolizumab plus chemotherapy for
non-squamous non-small cell lung cancer. Sci Rep. 2023 Mar 6;13(1):3698. doi:
10.1038/s41598-023-30676-y. PMID: 36878936; PMCID: PMC9988982.

7.

Goto Y, Shukuya T, Murata A, Kikkawa H, Emir B, Wiltshire R, Miura S. Real-world therapeutic
effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-celllung cancer. Cancer Sci. 2023 Mar 3. doi: 10.1111/cas.15777. PMID: 36866958.

8.

Miura S, Nishio M, Akamatsu H, Goto Y, Hayashi H, Gemma A, Yoshino I, Misumi T, Hata A,
Hataji O, Fujita K, Seike M, Yanagitani N, Nishino K, Hara S, Saito R, Mori M, Tsuda T,
Iwasawa S, Nakagawa S, Mitsudomi T. Effectiveness and Safety of Atezolizumab Monotherapy
in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A
Multicenter, Prospective, Observational Study (J-TAIL). JTO Clin Res Rep. 2023 Feb
24;4(3):100484. doi: 10.1016/j.jtocrr.2023.100484. PMID: 37034464; PMCID: PMC10074249.

9.

Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T,

Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E,
Hara S, Saito G, Miura S, Kanazu M, Yamamoto N, Akamatsu H. Outcomes ofChemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According
to Potential Clinical Trial Eligibility. JAMA Netw Open. 2023 Feb 1;6(2):e230698. doi:
10.1001/jamanetworkopen.2023.0698. PMID: 36826813; PMCID: PMC9958526.
10. Miura S, Koh Y, Azuma K, Yoshioka H, Koyama K, Teraoka S, Ishii H, Kibata K, Ozawa Y,
Tokito T, Oyanagi J, Shimokawa T, Kurata T, Yamamoto N, Tanaka H. Afatinib plus osimertinibin the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
BMC Cancer. 2023 Jan 3;23(1):6. doi: 10.1186/s12885-022-10467-w.PMID: 36597021-20221.

Watanabe S, Sakai K, Matsumoto N, Koshio J, Ishida A, Abe T, Ishikawa D, Tanaka T, Aoki A,
Kajiwara T, Koyama K, Miura S, Goto Y, Sekiya T, Suzuki R, Kushiro K, Fujisaki T,
Yanagimura N, Ohtsubo A, Shoji S, Nozaki K, Saida Y, Yoshizawa H, Nishio K, Kikuchi T.
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib
Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). Cancers(Basel). 2022 Dec 29;15(1):204. doi: 10.3390/cancers15010204.PMID: 36612200

2.

Qiu G, Li S, Li B, Yang Q, Deng H, Yang Y, Xie X, Lin X, Seki N, Miura S, Shukuya T, Zhou C,
Liu M. Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab:a case report. Transl Lung Cancer Res. 2022 Nov;11(11):2346-2355. doi:
10.21037/tlcr-22-745.PMID: 36519029

3.

Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, Goto Y, Takeshita M,
Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J,
Yamamoto N, Nakanishi Y, Okamoto I. Nab-Paclitaxel for Previously Treated Advanced
Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal
Impairment. Clin Lung Cancer. 2022 Nov;23(7):585-592. doi: 10.1016/j.cllc.2022.08.011. Epub
2022 Aug 22.PMID: 36114096

4.

Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, Furuya N,
Shiraishi Y, Harada T, Tanaka H, Miura S, Uchiyama A, Nakahara Y, Tokito T, Naoki K, Bessho
A, Goto Y, Seike M, Okamoto H. A Randomized Comparison of Nivolumab versus Nivolumab +Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung
Cancer: TORG1630. Clin Cancer Res. 2022 Oct 14;28(20):4402-4409. doi:
10.1158/1078-0432.CCR-22-1687.PMID: 35980349

5.

Ikeda S, Naito T, Miura S, Ito K, Furuya N, Misumi T, Ogura T, Kato T. Pharmacotherapy for
Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene
Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer? Cancers (Basel). 2022
Oct 5;14(19):4861. doi: 10.3390/cancers14194861.PMID: 36230785

6.

Miura S, Jung HA, Lee SY, Lee SH, Lee MK, Lee YC, Hochmair MJ, Yang CT, Märten A, Yang
JC, Popat S. Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive
Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global
Non-Interventional Studies. Onco Targets Ther. 2022 Aug 22;15:873-882. doi:
10.2147/OTT.S362535. eCollection 2022.PMID: 36033903

7.

Akamatsu H, Teraoka S, Takamori S, Miura S, Hayashi H, Hata A, Toi Y, Shiraishi Y, Mamesaya
N, Sato Y, Furuya N, Oyanagi J, Koh Y, Misumi T, Yamamoto N, Nakagawa K

Nivolumab

retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint
inhibitors and had ICI-free intervals (WJOG9616L). Clin Cancer Res. 2022 May
26:clincanres.0602.2022-2-23 04:31:47.850. doi: 10.1158/1078-0432.CCR-22-0602. Online
ahead of print.PMID: 35617519
8.

Shoji S, Miura S, Watanabe S, Ohtsubo A, Nozaki K, Saida Y, Ichikawa K, Kondo R, Tanaka T,
Koyama K, Tanaka H, Okajima M, Abe T, Ota T, Ishida T, Makino M, Iwashima A, Sato K,
Matsumoto N, Yoshizawa H, Kikuchi T. Phase II study of nanoparticle albumin-bound paclitaxel
monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes(NLCTG1302). Transl Lung Cancer Res. 2022 Jul;11(7):1359-1368. doi:
10.21037/tlcr-22-89.PMID: 35958345

9.

Shiraishi Y, Hakozaki T, Nomura S, Kataoka T, Tanaka K, Miura S, Sekino Y, Ando M,
Horinouchi H, Ohe Y, Okamoto I. A Multicenter, Randomized Phase III Study Comparing
Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination
Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell
Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). Clin Lung Cancer.
2022 Jun;23(4):e285-e288. doi: 10.1016/j.cllc.2021.10.012. Epub 2021 Oct 25.

10. Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K,
Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D,
Nakagawa K, Yamamoto N, Takahashi T. Randomized Phase 2 Study of Osimertinib Plus
Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring
EGFR Mutations: WJOG9717L Study. J Thorac Oncol. 2022 May 27:S1556-0864(22)00265-9.
doi: 10.1016/j.jtho.2022.05.006.
11. Yang JC, Schuler M, Popat S, Miura S, Park K, Passaro A, De Marinis F, Solca F, Märten A,
Kim ES. Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring
Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report. Front Oncol.
2022 Apr 28;12:834704. doi: 10.3389/fonc.2022.834704. eCollection 2022
12. Koyama K, Miura S, Watanabe S, Shoji S, Koshio J, Hayashi Y, Ishikawa D, Sato K,
Miyabayashi T, Okajima M, Ota T, Tanaka T, Matsumoto N, Kuriyama H, Abe T, Nozaki K,
Ichikawa K, Kondo R, Tanaka H, Kikuchi T. Observational study of rebiopsy in
EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC. .Sci Rep. 2022
Apr 16;12(1):6367. doi: 10.1038/s41598-022-10288-8.
13. Popat S, Hsia TC, Hung JY, Jung HA, Shih JY, Park CK, Lee SH, Okamoto T, Ahn HK, Lee YC,
Sato Y, Lee SS, Mascaux C, Daoud H, Märten A, Miura S. Tyrosine Kinase Inhibitor Activity inPatients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International
Cohort Study (UpSwinG). Oncologist. 2022 Apr 5;27(4):255-265. doi: 10.1093/oncolo/oyac022.
14. Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J,
Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K,
Yamamoto N, Nakagawa K. A Randomized Phase II Study Comparing Nivolumab with
Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase
Inhibitors (WJOG8515L). Clin Cancer Res. 2022 Mar 1;28(5):893-902. doi:10.1158/1078-0432.CCR-21-3194.
15. Fujimoto D, Akamatsu H, Morimoto T, Wakuda K, Sato Y, Kawa Y, Yokoyama T, Tamiya M,
Hiraoka R, Shingu N, Ikeda H, Tamiya A, Kanazu M, Miyauchi E, Miura S, Yanai M, Yomota
M, Morinaga R, Yokoi T, Hata A, Suzuki H, Matsumoto H, Sakata S, Furuya N, Harutani Y,
Nakachi I, Otsuki A, Uematsu S, Hara S, Yokoo K, Sugimoto T, Yamamoto N. Histologictransformation of epidermal growth factor receptor-mutated lung cancer. Eur J Cancer. 2022 Mar
9;166:41-50. doi: 10.1016/j.ejca.2022.02.006. Online ahead of print.
16. Ichikawa K, Watanabe S, Miura S, Ohtsubo A, Shoji S, Nozaki K, Tanaka T, Saida Y, Kondo R,
Hokari S, Aoki N, Ohshima Y, Koya T, Kikuchi T. Prognostic significance of procalcitonin insmall cell lung cancer. Transl Lung Cancer Res. 2022 Jan;11(1):43-52. doi: 10.21037/tlcr-21-838.
17. Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y,
Haratani K, Tamiya M, Ikeda S, Miura S, Tanizaki J, Omori S, Yoshioka H, Hata A, Yamamoto
N, Nakagawa K. Real-world data on NGS using the Oncomine DxTT for detecting genetic
alterations in non-small-cell lung cancer: WJOG13019L. Cancer Sci. 2022 Jan;113(1):221-228.
doi: 10.1111/cas.15176. Epub 2021 Nov 7.
-202118. Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Haratani K, Itoh S, Uemura T, Morinaga
R, Takahama T, Nakashima K, Tachihara M, Saito G, Tanizaki J, Otsubo K, Ikeda S, Matsumoto
H, Hara S, Hata A, Masuda T, Yamamoto N. A Real-World Study on the Effectiveness and Safetyof Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. JTO Clin Res Rep. 2021 Dec
16;3(2):100265. doi: 10.1016/j.jtocrr.2021.100265. eCollection 2022
19. Yamaguchi H, Wakuda K, Fukuda M, Kenmotsu H, Mukae H, Ito K, Chibana K, Inoue K, Miura
S, Tanaka K, Ebi N, Suetsugu T, Harada T, Kirita K, Yokoyama T, Nakatani Y, Yoshimura K,
Nakagawa K, Yamamoto N, Sugio K. A Phase II Study of Osimertinib for Radiotherapy-Naive
Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN
Study (LOGIK1603/WJOG9116L). J Thorac Oncol. 2021 Dec;16(12):2121-2132. doi:
10.1016/j.jtho.2021.07.026. Epub 2021 Aug 19.
20. Shiraishi Y, Hakozaki T, Nomura S, Kataoka T, Tanaka K, Miura S, Sekino Y, Ando M,
Horinouchi H, Ohe Y, Okamoto I. A Multicenter, Randomized Phase III Study Comparing
Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination
Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell
Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). Clin Lung Cancer.
2021 Oct 25:S1525-7304(21)00271-0. doi: 10.1016/j.cllc.2021.10.012.
21. Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K,
Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S,
Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T,
Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T,
Hotta K, Takiguchi Y. Japanese Lung Cancer Society Guidelines for Stage IV NSCLCWith EGFR Mutations. JTO Clin Res Rep. 2020 Oct 12;2(1):100107. doi:
10.1016/j.jtocrr.2020.100107. eCollection 2021 Jan.PMID: 34589972
22. Popat S, Jung HA, Lee SY, Hochmair MJ, Lee SH, Escriu C, Lee MK, Migliorino MR, Lee YC,

Girard N, Daoud H, Märten A, Miura S. Sequential afatinib and osimertinib in patients with
EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study(UpSwinG). Lung Cancer. 2021 Sep 21;162:9-15. doi: 10.1016/j.lungcan.2021.09.009. Online
ahead of print.PMID: 34649106
23. Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, Goto Y, Takeshita M,
Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J,
Yamamoto N, Nakanishi Y, Okamoto I. Phase 3 Trial Comparing Nanoparticle Albumin-Bound
Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. J Thorac Oncol. 2021
Sep;16(9):1523-1532. doi: 10.1016/j.jtho.2021.03.027. Epub 2021 Apr 27.PMID: 33915251
24. Sato Y, Watanabe S, Ota T, Kushiro K, Fujisaki T, Takahashi M, Ohtsubo A, Shoji S, Nozaki K,
Ichikawa K, Hokari S, Kondo R, Hayashi M, Ishikawa H, Miyabayashi T, Abe T, Miura S,
Tanaka H, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Ohshima
Y, Koya T, Kikuchi T. Subsequent systemic therapy for non-small cell lung cancer patients withimmune checkpoint inhibitor-related interstitial lung disease. Transl Lung Cancer Res. 2021
Jul;10(7):3132-3143. doi: 10.21037/tlcr-21-198.PMID: 34430353
25. Fujisaki T, Watanabe S, Ota T, Kushiro K, Sato Y, Takahashi M, Ohtsubo A, Shoji S, Nozaki K,
Ichikawa K, Hokari S, Kondo R, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada
M, Matsumoto N, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Hayashi M, Ohshima Y,
Koya T, Kikuchi T. The Prognostic Significance of the Continuous Administration of Anti-PD-1
Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse
Events. Front Oncol. 2021 Sep 24;11:704475. doi: 10.3389/fonc.2021.704475. eCollection
2021.PMID: 34631533
26. Yamaguchi H, Wakuda K, Fukuda M, Kenmotsu H, Mukae H, Ito K, Chibana K, Inoue K, Miura
S, Tanaka K, Ebi N, Suetsugu T, Harada T, Kirita K, Yokoyama T, Nakatani Y, Yoshimura K,
Nakagawa K, Yamamoto N, Sugio K. A Phase II Study of Osimertinib for Radiotherapy-Naive
Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN
Study (LOGIK1603/WJOG9116L). J Thorac Oncol. 2021 Aug 19:S1556-0864(21)02372-8. doi:
10.1016/j.jtho.2021.07.026. Online ahead of print.PMID: 34419684
27. Tatematsu N, Naito T, Okayama T, Tsuji T, Iwamura A, Tanuma A, Mitsunaga S, Miura S, Omae
K, Mori K, Takayama K. Development of home-based resistance training for older patients withadvanced cancer: The exercise component of the nutrition and exercise treatment for advanced
cancer program. J Geriatr Oncol. 2021 Jul;12(6):952-955. doi: 10.1016/j.jgo.2021.03.006. Epub
2021 Mar 17.PMID: 33744182
28. Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya
M, Nakamura A, Yoshioka H, Haratani K, Teraoka S, Tokito T, Murakami S, Tamiya A, Itoh S,
Yokouchi H, Watanabe S, Yamaguchi O, Tomii K, Yamamoto N. Pembrolizumab plus
chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small celllung cancer: A multicentre, retrospective cohort study. Eur J Cancer. 2021 Jun;150:63-72. doi:
10.1016/j.ejca.2021.03.016. Epub 2021 Apr 20. PMID: 33892408
29. Ito K, Yamanaka T, Hayashi H, Hattori Y, Nishino K, Kobayashi H, Oya Y, Yokoyama T, Seto T,
Azuma K, Fukui T, Kozuki T, Nakamura A, Tanaka K, Hirano K, Yokoi T, Daga H, Sakata S,
Fujimoto D, Mori M, Maeno K, Aoki T, Tamura A, Miura S, Watanabe S, Akamatsu H, Hataji O,

Suzuki K, Hontsu S, Azuma K, Bessho A, Kubo A, Okuno M, Nakagawa K, Yamamoto N.
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring
anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort
study. Eur J Cancer. 2021 Mar;145:183-193. doi: 10.1016/j.ejca.2020.12.026. Epub 2021 Jan
22.PMID: 33486442
30. Okajima M, Miura S, Watanabe S, Tanaka H, Ito K, Ishida T, Makino M, Iwashima A,
Matsumoto N, Sato K, Ichikawa K, Abe T, Yoshizawa H, Kikuchi T. A prospective phase II studyof multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small
cell lung cancer (Niigata Lung Cancer Treatment Group 1401). Transl Lung Cancer Res. 2021
Jan;10(1):252-260. doi: 10.21037/tlcr-20-649.PMID: 33569309-202031. Miura S, Yamanaka T, Kato T, et al. Epub 2020 May 21. Treatment Rationale and Design of a
Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer
Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations(ACHILLES/TORG1834). Clin Lung Cancer 2020 Nov;21(6):e592-e596. doi:
10.1016/j.cllc.2020.05.011.
32. Tanaka K, Morita S, Ando M, Yokoyama T, Nakamura A, Yoshioka H, Ishiguro T, Miura S,
Toyozawa R, Oguri T, Daga H, Ko R, Bessho A, Tachihara M, Iwamoto Y, Hirano K, Nakanishi
Y, Nakagawa K, Yamamoto N, Okamoto I. A randomized phase 3 study of maintenance therapy
with S-1 plus best supportive care versus best supportive care after induction therapy withcarboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung
(WJOG7512L). Cancer. 2020 Aug 15;126(16):3648-3656. doi: 10.1002/cncr.32987. Epub 2020
Jun 2.PMID: 32484914
33. Watanabe S, Ota T, Hayashi M, Ishikawa H, Otsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R,
Miyabayashi T, Miura S, Tanaka H, Abe T, Okajima M, Terada M, Ishida T, Iwashima A, Sato K,
Yoshizawa H, Kikuchi T. Prognostic significance of the radiologic features of pneumonitis
induced by anti-PD-1 therapy. Cancer Med. 2020 May;9(9):3070-3077. doi: 10.1002/cam4.2974.
Epub 2020 Mar 9. PMID: 32150668
34. Wakuda K, Yamaguchi H, Kenmotsu H, Fukuda M, Takeshita M, Suetsugu T, Kirita K, Ebi N,
Hataji O, Miura S, Chibana K, Okamoto I, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K.
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of
non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study(LOGIK 1603/WJOG 9116L). BMC Cancer. 2020 May 1;20(1):370. doi:
10.1186/s12885-020-06874-6.
35. Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES. Afatinib for theTreatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J
Thorac Oncol. 2020 Jan 10. pii: S1556-0864(20)30014-9. doi: 10.1016/j.jtho.2019.12.126.
-201936. Shoji S, Hosojima M, Kabasawa H, Kondo R, Miura S, Watanabe S, Aoki N, Kaseda R,
Kuwahara S, Tanabe N, Hirayama Y, Narita I, Kikuchi T, Kagamu H, Saito A. Correlation ofprechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of
cisplatin-induced nephrotoxicity: a prospective observational study.

BMC Cancer. 2019 Dec

2;19(1):1170. doi: 10.1186/s12885-019-6398-2.
37. Saida Y, Watanabe S, Abe T, Shoji S, Nozaki K, Ichikawa K, Kondo R, Koyama K, Miura S,
Tanaka H, Okajima M, Terada M, Ishida T, Tsukada H, Makino M, Iwashima A, Sato K,
Matsumoto N, Yoshizawa H, Kikuchi T. Efficacy of EsGFR-TKIs with or without upfront brain
radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases. Thorac
Cancer. 2019 Nov;10(11):2106-2116. doi: 10.1111/1759-7714.13189. Epub 2019 Sep 10.
38. Miura S, Naito T, Mitsunaga S, et al. A randomized phase II study of nutritional and exercise
treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the
NEXTAC-TWO study protocol. BMC Cancer. 2019 May 31;19(1):528. doi:
10.1186/s12885-019-5762-6.
39. Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki
T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R,
Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S,
Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto
N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J
Clin Oncol. 2019 Jul;24(7):731-770. doi: 10.1007/s10147-019-01431-z. Epub 2019 May 2.
40. Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S,
Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S,
Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. AXL
confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat
Commun. 2019 Jan 16;10(1):259
41. Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H, Uemura K, Morita S,
Yamamoto N. The impact of high PD-L1 expression on the surrogate endpoints and clinicaloutcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Lung Cancer. 2019
Feb;128:113-119.
42. Naito T, Mitsunaga S, Miura S, Tatematsu N, Inano T, Mouri T, Tsuji T, Higashiguchi T, Inui A,
Okayama T, Yamaguchi T, Morikawa A, Mori N, Takahashi T, Strasser F, Omae K, Mori K,
Takayama K. Feasibility of early multimodal interventions for elderly patients with advanced
pancreatic and non-small-cell lung cancer. J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):73-83.
-201843. Mouri T, Naito T, Morikawa A, Tatematsu N, Miura S, Okayama T, Omae K, Takayama K.
Promotion of Behavioral Change and the Impact on Quality of Life in Elderly Patients with
Advanced Cancer: A Physical Activity Intervention of the Multimodal Nutrition and Exercise
Treatment for Advanced Cancer Program. Asia Pac J Oncol Nurs. 2018 Oct-Dec;5(4):383-390.
-201744. Miura S, Maemondo M, Iwashima A, et al. A phase II study of carboplatin plus weekly paclitaxel
with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
Invest New Drugs. 2017 35(2):227-234.

45. Yoneshima Y, Morita S, Ando M, Miura S, Yoshioka H, et al. Treatment Rationale and Design
for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients
With Previously Treated Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017;18(1):100-103.
-201646. Sato K, Watanabe S, Ohtsubo A, Shoji S, Ishikawa D, Tanaka T,…, Miura S, et al.
Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients withCKD risk factors. BMC Cancer. 2016;16:222.
-201547. Saida Y, Watanabe S, Tanaka T, Baba J, Sato K, Shoji S, …, Miura S, et al. Critical Roles ofChemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting
Chemotherapy. J Immunol. 2015;195:726-35.
48. Miura S, Kaira K, Kaira R, Akamatsu H, Ono A, Shukuya T, et al. The efficacy of amrubicin on
central nervous system metastases originating from small-cell lung cancer: a case series of eightpatients. Investigational New Drugs. 2015;33:755-60.
49. Miura S, Kagamu H, Sakai T, Nozaki K, Asakawa K, Moro H, et al. Advanced thymic cancer
treated with carboplatin and paclitaxel in a patient undergoing hemodialysis. Intern Med.
2015;54:55-8.
50. Aoki A, Moro H, Watanabe T, Asakawa K, Miura S, Moriyama M, et al. A case of severe
thrombocytopaenia associated with acute HIV-1 infection. International journal of STD & AIDS.
2015;26:209-11.
-201451. Nozaki K, Kagamu H, Shoji S, Igarashi N, Ohtsubo A, Okajima M, Miura S, et al. DDX3X
induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells
harboring EGFR-activating mutations. PloS ONE. 2014;9:e111019.
52. Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, …, Miura S, et al. A
phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR
gene mutation who have never/light smoking history: re-evaluation of EGFR gene status(NEJ006/TCOG0903). Lung Cancer. 2014;86:195-200.
53. Kondo R, Watanabe S, Ishikawa D, Tanaka T, Ohshima Y, Asakawa K, …, Miura S, et al. [Acase of thymic cancer effectively treated by weekly paclitaxel combined with carboplatin]. Gan
To Kagaku Ryoho. 2014;41:2607-9.
-201354. Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, et al. The efficacy of triplet
antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting
in lung cancer patients receiving highly emetogenic chemotherapy. Support Care Cancer.
2013;21:2575-81.
55. Koshio J, Kagamu H, Nozaki K, Saida Y, Tanaka T, Shoji S, …, Miura S, et al. DEAD/H

(Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem
cells. Cancer Immunol Immunother. 2013;62:1619-28.
56. Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, et al. Interstitial lung diseaseassociated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res.
2012;32:1103-6.
-201257. Miura S, Kagamu H, Saijyo Y. [Management of bone metastasis originating from lung cancer].
Gan To Kagaku Ryoho. 2012;39:1183-6.
58. Ichikawa K, Kagamu H, Koyama K, Miyabayashi T, Koshio J, Miura S, et al. Epitope
diversification driven by non-tumor epitope-specific Th1 and Th17 mediates potent antitumor
reactivity. Vaccine. 2012;30:6190-7.
59. Baba J, Watanabe S, Saida Y, Tanaka T, Miyabayashi T, Koshio J, …, Miura S, et al. Depletionof radio-resistant regulatory T cells enhances antitumor immunity during recovery fromlymphopenia. Blood. 2012;120:2417-27.
-201160. Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, et al. Expression of Excision Repair
Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and beta III-Tubulin in Thymic
Epithelial Tumors. J Thorac Oncol. 2011;6:606-13.
61. Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, et al. Expression of thymidylate
synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic
epithelial tumors. Lung Cancer. 2011;74:419-25.
62. Kaira K, Murakami H, Miura S, Kaira R, Akamatsu H, Kimura M, et al. 18F-FDG uptake on
PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors.
Ann Nucl Med. 2011;25:247-53.

-201063. Miura S, Yamamoto N. [Combined-modality therapy for lung cancer]. Nippon Rinsho.
2010;68:1121-8.
-200864. Miura S, Kagamu H, Tanaka H, Yoshizawa H, Gejyo F. Appropriate timing of CD40 ligation for
RNA-Pulsed DCs to induce antitumor immunity. Scand J Immunol. 2008;67:385-91.
65. Koyama K, Kagamu H, Miura S, Hiura T, Miyabayashi T, Itoh R, et al. Reciprocal CD4+ T-cellbalance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small
cell lung cancer reflects disease stage. Clin Cancer Res. 2008;14:6770-9.
-200566. Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J, et al. Both regulatory T cells andantitumor effector T cells are primed in the same draining lymph nodes during tumor
progression. J Immunol. 2005;175:5058-66.